about
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target moleculeZoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cellsMelphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.A comparison of allografting with autografting for newly diagnosed myeloma.Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.New drugs for treatment of multiple myeloma.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method.CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells?Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.Idiotypic vaccination in B-cell malignancies.The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients.Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma.Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone.Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.Chicago 2014--30 years of γδ T cells.Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialIGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
P50
Q27015933-C7086C18-E014-4A47-B54B-632A08B01B27Q28486174-167E7BC0-BD46-423B-BD9E-73CFA473E743Q33387332-ABE45E48-9F92-4237-95B5-FB992C0BEB15Q34577703-CE468C4E-3CC2-4D5B-8CC3-526355F3D798Q34973576-0746BD43-848D-4BE8-9E21-328BA3A8B6A8Q35651684-9DF6925C-CF1C-4203-BDA5-33427B9C0840Q35824983-63CF1C75-7935-4576-BF6F-3639171F2874Q36550468-B7D7B012-5553-41E7-9311-15E16E3DD15BQ36557448-7D4AC937-77A1-457D-80D6-94915BB125E5Q37294327-E58F10EF-61A4-42AD-B9E2-B6DF8352A45FQ37709461-11F87AAF-93AC-4998-BC2B-F4561C1DDE88Q37876363-25E97668-BFC7-491D-9A17-FF51B760A672Q38027044-3D1EA757-629A-4B2F-91AC-C93026E402B2Q38688055-1931BA0F-2D84-496D-B272-BEE001056C09Q39848077-6265E4A9-D261-4AC7-87A1-56F149855E7CQ40040623-D946E310-08A1-474F-8BF6-F7BE922F118DQ40197317-3BD378BB-8D87-4AEC-8E51-181F05D26CBBQ40540551-FA78E120-6C21-4BB1-925C-DACEEBD6BCA1Q41578214-5C5A9313-8ABE-4987-92A1-317DDA3BA246Q41633628-52C84394-53B5-4361-88F2-EBC97401086AQ41773489-3E31F0BB-78DD-4D62-97C1-5AD04B15DE7BQ42211743-A48CFEE5-8FD9-4377-8670-B5D50F840094Q42248813-79766200-29C8-405A-A2BA-3A5B2D81870BQ42631830-9A1DB003-60E7-48C1-8CA3-D3A227DE7AE1Q42847556-6F2ABC4C-23D8-4C08-91BC-A69AF9E8FC4BQ43135377-673053B3-16AA-4E9E-B4A2-0E9875241E5AQ43146957-6C1FD3E7-FE6E-47D0-85EE-D65A16EE9681Q43800903-0B38C6D4-BDEA-473C-BF57-7F35F8C16E52Q45202285-804E4D23-3B3F-458C-A3D2-4C8062FB3E7BQ45296414-1EF1AFE1-62E2-45EC-90FA-36348BC01C3AQ46394690-E5B6034E-EFC4-4DBD-8B00-BA5EFC82E21FQ47094907-AA26AAD9-3889-4EB4-80E8-C4D28A9590B0Q48335780-6156873B-1F62-45CE-9C8F-167D09E0422AQ51570860-E854DE3C-4C9C-40BE-9218-25D432F0CE47Q52018830-FCBC74A5-ACE3-44E3-93E1-E228203FF897Q52597560-F873B743-495E-472A-8AA9-E6E4084AF9F2Q52646820-6F6889AC-A86D-4A68-88CE-09F6706ED9CDQ54703524-6B6160BD-7BFB-4DF5-944C-0764074BE28BQ59650507-ABE64966-11A4-4EAD-BC15-1BDB3F4D4064Q60617037-C136FD9E-667B-40DD-A544-7FF3A3DC945A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Massaia
@ast
Massimo Massaia
@en
Massimo Massaia
@es
Massimo Massaia
@nl
Massimo Massaia
@sl
type
label
Massimo Massaia
@ast
Massimo Massaia
@en
Massimo Massaia
@es
Massimo Massaia
@nl
Massimo Massaia
@sl
prefLabel
Massimo Massaia
@ast
Massimo Massaia
@en
Massimo Massaia
@es
Massimo Massaia
@nl
Massimo Massaia
@sl
P106
P1153
7005447404
P21
P31
P496
0000-0002-0021-1428